Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Given Consensus Recommendation of “Moderate Buy” by Analysts

Posted by Francis Steltz on May 31st, 2026

Shares of Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the fifteen ratings firms that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and eleven have given a buy recommendation to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $59.00.

Several brokerages have commented on LEGN. Rothschild & Co Redburn downgraded Legend Biotech from a “buy” rating to a “neutral” rating and set a $24.00 target price for the company. in a research note on Thursday, February 12th. TD Cowen upped their price objective on Legend Biotech to $29.00 and gave the company a “hold” rating in a research note on Wednesday, May 13th. Royal Bank Of Canada upped their price objective on Legend Biotech from $62.00 to $64.00 and gave the company an “outperform” rating in a research note on Wednesday, May 13th. HC Wainwright reaffirmed a “buy” rating on shares of Legend Biotech in a research note on Wednesday. Finally, Truist Financial downgraded Legend Biotech from a “strong-buy” rating to a “hold” rating in a research note on Friday, March 20th.

Get Our Latest Report on LEGN

Legend Biotech Stock Down 3.9%

LEGN opened at $27.16 on Friday. Legend Biotech has a twelve month low of $16.24 and a twelve month high of $45.30. The company has a 50-day simple moving average of $23.15 and a 200 day simple moving average of $22.41. The stock has a market capitalization of $5.02 billion, a price-to-earnings ratio of -39.94 and a beta of 0.29.

Legend Biotech (NASDAQ:LEGN – Get Free Report) last issued its earnings results on Wednesday, May 13th. The company reported ($0.03) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.01). The business had revenue of $305.10 million for the quarter, compared to analyst estimates of $306.51 million. Legend Biotech had a negative return on equity of 24.92% and a negative net margin of 21.98%.The firm’s revenue was up 56.5% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.07) EPS. Sell-side analysts anticipate that Legend Biotech will post 0.2 EPS for the current fiscal year.

Insider Activity

In other news, CEO Ying Huang sold 9,936 shares of the company’s stock in a transaction that occurred on Wednesday, March 25th. The stock was sold at an average price of $8.77, for a total value of $87,138.72. Following the completion of the transaction, the chief executive officer owned 247,438 shares of the company’s stock, valued at $2,170,031.26. This represents a 3.86% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 0.02% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Clearstead Advisors LLC increased its stake in shares of Legend Biotech by 76.5% in the third quarter. Clearstead Advisors LLC now owns 847 shares of the company’s stock valued at $28,000 after buying an additional 367 shares during the period. Parallel Advisors LLC increased its position in Legend Biotech by 171.9% during the 3rd quarter. Parallel Advisors LLC now owns 1,047 shares of the company’s stock valued at $34,000 after purchasing an additional 662 shares during the period. Caitong International Asset Management Co. Ltd increased its position in Legend Biotech by 1,730.3% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,569 shares of the company’s stock valued at $78,000 after purchasing an additional 3,374 shares during the period. Raymond James Financial Inc. acquired a new stake in Legend Biotech during the 2nd quarter valued at approximately $78,000. Finally, IFM Investors Pty Ltd acquired a new stake in Legend Biotech during the 1st quarter valued at approximately $81,000. Institutional investors and hedge funds own 70.89% of the company’s stock.

About Legend Biotech

(Get Free Report)

Legend Biotech (NASDAQ: LEGN) is a commercial-stage biopharmaceutical company specializing in the development and commercialization of chimeric antigen receptor T-cell (CAR-T) therapies for oncology. Headquartered in Somerset, New Jersey, with research and development operations in Shanghai, the company leverages a global infrastructure to advance innovative cellular therapies. Legend Biotech pursues a strategy of strategic collaboration to extend its reach, most notably through its partnership with Janssen Biotech, a subsidiary of Johnson & Johnson.

The company’s lead asset, ciltacabtagene autoleucel (commercially marketed as Carvykti), is a B-cell maturation antigen (BCMA)–directed CAR-T therapy for the treatment of relapsed or refractory multiple myeloma.